Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Tranzyme Pharma
Private Company Edition: Venture capital mega-rounds continue to add up, including recent financings for Connect Biopharma ($115m) and Synthego ($100m). Also, Civilization Ventures closed a new $35m fund and Triumvira launched with $55m.
Pandemic-related collaborations between Hoth/VCU; Sorrento/Mt. Sinai Health; Audax/Northeastern U.; Alkido/U. of Maryland, Baltimore; Active Motif/Hisun BioRay/Fudan U. and more.
Tenaya is working on three separate approaches (gene therapy, cell therapy and small molecule) to develop new treatments for heart disease.
Private Company Edition: Revolution Medicines follows its Sanofi partnership and Warp Drive Bio buyout with a series C venture capital round to fund its RAS pathway inhibitors in cancer. The financing came during a boom in $100m-plus VC financings, including BioNTech's $325m series B.
- Drug Discovery Tools